Interleukin-1 as a therapeutic target in gout

被引：56

作者：

Dumusc, Alexandre ^{[1
]}

So, Alexander ^{[1
]}

机构：

[1] CHU Vaudois, Univ Lausanne Hosp, Dept Rheumatol, CH-1011 Lausanne, Switzerland

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2015年 / 27卷 / 02期

关键词：

anakinra; canakinumab; gout; interleukin-1; inflammasome; rilonacept; PLACEBO-CONTROLLED TRIAL; NLRP3; INFLAMMASOME; DOUBLE-BLIND; FLARE PREVENTION; PHASE-II; ARTHRITIS; ANAKINRA; CANAKINUMAB; RILONACEPT; EFFICACY;

D O I：

10.1097/BOR.0000000000000143

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of review To give an overview of current evidence for interleukin (IL)-1 blockade in the management of gout. Recent findings Three IL-1 blockers are currently available for clinical use: anakinra, rilonacept and canakinumab. Recent studies have focused on drugs with a long half-life: rilonacept and canakinumab. For treatment of acute gouty arthritis, three randomized controlled trials (RCTs) showed efficacy of canakinumab with some safety concerns and one RCT failed to show efficacy of rilonacept. For prevention of gout flare when starting uric acid lowering therapy (ULT), four RCTs showed efficacy of rilonacept and one RCT showed efficacy of canakinumab. Summary There is sufficient evidence supporting the use of IL-1 blockers for treatment of acute gouty arthritis or for prevention of gout flares when starting ULT in selected patients, with contraindications or intolerance to conventional therapy. More data are needed to assess safety and to specify their use in routine practice.

引用

页码：156 / 163

页数：8

共 36 条

[1]

Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure [J].

Announ, Nadia ;

Palmer, Gaby ;

Gueme, Pierre-Andre ;

Gabay, Cem .

JOINT BONE SPINE, 2009, 76 (04) :424-426

[2]

Glucocorticoids Sensitize the Innate Immune System through Regulation of the NLRP3 Inflammasome [J].

Busillo, John M. ;

Azzam, Kathleen M. ;

Cidlowski, John A. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (44) :38703-38713

[3]

Mechanisms of inflammation in gout [J].

Busso, Nathalie ;

So, Alexander .

ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)

[4]

Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases [J].

Chen, Kun ;

Fields, Theodore ;

Mancuso, Carol A. ;

Bass, Anne R. ;

Vasanth, Lisa .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (03) :210-214

[5]

Efficacy of anakinra in articular chondrocalcinosis: Report of three cases [J].

Couderc, Marion ;

Mathieu, Sylvain ;

Glace, Baptiste ;

Soubrier, Martin .

JOINT BONE SPINE, 2012, 79 (03) :330-331

[6]

Mechanism of Action of Colchicine in the Treatment of Gout [J].

Dalbeth, Nicola ;

Lauterio, Thomas J. ;

Wolfe, Henry R. .

CLINICAL THERAPEUTICS, 2014, 36 (10) :1465-1479

[7]

Interleukin 1β Blockade Improves Signs and Symptoms of Chronic Calcium Pyrophosphate Crystal Arthritis Resistant to Treatment [J].

Diamantopoulos, Andreas P. ;

Brodin, Christer ;

Hetland, Helene ;

Haugeberg, Glenn .

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2012, 18 (06) :310-311

[8]

European Medicines Agency (EMA), 2009, RIL REG EPAR PUBL AS

[9]

Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra [J].

Ghosh, Pradipta ;

Cho, Michael ;

Rawat, Gurpreet ;

Simkin, Peter A. ;

Gardner, Gregory C. .

ARTHRITIS CARE & RESEARCH, 2013, 65 (08) :1381-1384

[10]

Inflammasome Activators Induce Interleukin-1α Secretion via Distinct Pathways with Differential Requirement for the Protease Function of Caspase-1 [J].

Gross, Olaf ;

Yazdi, Amir S. ;

Thomas, Christina J. ;

Masin, Mark ;

Heinz, Leonhard X. ;

Guarda, Greta ;

Quadroni, Manfredo ;

Drexler, Stefan K. ;

Tschopp, Jurg .

IMMUNITY, 2012, 36 (03) :388-400

← 1 2 3 4 →